OYE Therapeutics Raises $5.475 Million Series A to Advance High-Concentration Caffeine Therapy. WBB Securities LLC acted as the placement agent for the Series A financing.
Read More about OYE Therapeutics Raises $5.475 Million Series A to Advance High-Concentration Caffeine TherapyWBB Securities today announced it had acted as the sole placement agent for a $9 million Series A funding round for FELIQS, a biotechnology company developing first-in-class small molecule therapeutics for rare pediatric retinal diseases.
Read More about WBB Securities acted as the sole placement agent for a $9 million Series A funding round for FELIQS
WBB Securities invites you to attend the upcoming Demy-Colton Virtual Salon titled:
“Seven Years After FDA Approval: What Have We Learned About Cell and Gene Therapies?”.
The Need for Novel Responses to Disease Threats in a Fast-Changing World.
Read More about Dr. Steve Brozak, President of WBB Securities, will moderate a panel at the Biotech Showcase Conference on Wednesday, January 15, 2025, titled “The Need for Novel Responses to Disease Threats in a Fast-Changing World.”On Thursday, October 19, 2023, the WBB Research Institute and the Foreign Policy Association will sponsor an important forum at the United Nations titled “A Tale of Two Pandemics: 1889 & 2019, Insights for Pandemic Preparedness.”
The forum will examine how responses to prior influenza pathogens predicated global responses to Covid.
For Immediate Release October 13, 2023 Cranford, NJ– On Thursday, October 19th, WBB Research Institute and the Foreign Policy Association will sponsor an important forum at the United Nations, examining how responses to prior influenza […]
Read More about WBB Research Institute and the Foreign Policy Association will sponsor an important forum at the United Nations: “A Tale of Two Pandemics: Lessons from the 1889 & 2019 Pandemics”